These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 7594643)
1. Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity. Chen C; Puy LA; Simard J; Li X; Singh SM; Labrie F J Invest Dermatol; 1995 Nov; 105(5):678-82. PubMed ID: 7594643 [TBL] [Abstract][Full Text] [Related]
2. Activity of 17beta-(N-alkyl/arylformamido) and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. Chen C; Li X; Singh SM; Labrie F J Invest Dermatol; 1998 Aug; 111(2):273-8. PubMed ID: 9699729 [TBL] [Abstract][Full Text] [Related]
3. The effects of a nonsteroid antiandrogen, flutamide, on sebaceous gland activity. Lutsky BN; Budak M; Koziol P; Monahan M; Neri RO J Invest Dermatol; 1975 Jun; 64(6):412-7. PubMed ID: 1141714 [TBL] [Abstract][Full Text] [Related]
4. Adrenal steroid precursors exert potent androgenic action in the hamster sebaceous glands of flank organs and ears. Chen C; Belanger A; Labrie F Endocrinology; 1996 May; 137(5):1752-7. PubMed ID: 8612511 [TBL] [Abstract][Full Text] [Related]
5. Effects of topically applied antiandrogenic compounds on sebaceous glands of hamster ears and flank organs. Schröder HG; Ziegler M; Nickisch K; Kaufmann J; el Etreby MF J Invest Dermatol; 1989 May; 92(5):769-73. PubMed ID: 2715647 [TBL] [Abstract][Full Text] [Related]
6. Topical anti-androgenicity of a new 4-azasteroid in the hamster. Brooks JR; Primka RL; Berman C; Krupa DA; Reynolds GF; Rasmusson GH Steroids; 1991 Aug; 56(8):428-33. PubMed ID: 1788861 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies. Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152 [TBL] [Abstract][Full Text] [Related]
8. Antiandrogenic effects of topically applied spironolactone on the hamster flank organ. Weissmann A; Bowden J; Frank BL; Horwitz SN; Frost P Arch Dermatol; 1985 Jan; 121(1):57-62. PubMed ID: 3155605 [TBL] [Abstract][Full Text] [Related]
9. Effects of topical antiandrogen and 5-alpha-reductase inhibitors on sebaceous glands in male fuzzy rats. Ye F; Imamura K; Imanishi N; Rhodes L; Uno H Skin Pharmacol; 1997; 10(5-6):288-97. PubMed ID: 9449168 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613 [TBL] [Abstract][Full Text] [Related]
12. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Imada S; Akaza H; Ami Y; Koiso K; Ideyama Y; Takenaka T Eur Urol; 1997; 31(3):360-4. PubMed ID: 9129932 [TBL] [Abstract][Full Text] [Related]
13. Growth suppression of hamster flank organs by topical application of gamma-linolenic and other fatty acid inhibitors of 5alpha-reductase. Liang T; Liao S J Invest Dermatol; 1997 Aug; 109(2):152-7. PubMed ID: 9242500 [TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
15. Effect of 13-cis-retinoic acid on the hamster flank organ. Gomez EC; Moskowitz RJ J Invest Dermatol; 1980 Jun; 74(6):392-7. PubMed ID: 7381230 [TBL] [Abstract][Full Text] [Related]
16. The abnormal development of male sex organs in the rat using a pure antiandrogen and a 5 alpha-reductase inhibitor during gestation. Hib J; Ponzio R Acta Physiol Pharmacol Ther Latinoam; 1995; 45(1):27-33. PubMed ID: 8580516 [TBL] [Abstract][Full Text] [Related]
17. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Barqawi AB; Moul JW; Ziada A; Handel L; Crawford ED Urology; 2003 Nov; 62(5):872-6. PubMed ID: 14624911 [TBL] [Abstract][Full Text] [Related]
18. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431 [TBL] [Abstract][Full Text] [Related]
19. [Effects of androgen regulation system on bladder carcinogenesis in male mice]. Imada S; Akaza H; Otani M; Koiso K Nihon Hinyokika Gakkai Zasshi; 1995 Nov; 86(11):1666-72. PubMed ID: 8551710 [TBL] [Abstract][Full Text] [Related]
20. Comparison of anti-androgenic activity of flutamide, vinclozolin, procymidone, linuron, and p, p'-DDE in rodent 10-day Hershberger assay. Kang IH; Kim HS; Shin JH; Kim TS; Moon HJ; Kim IY; Choi KS; Kil KS; Park YI; Dong MS; Han SY Toxicology; 2004 Jul; 199(2-3):145-59. PubMed ID: 15147789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]